Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

171
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
171
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

162
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
162
Dementia01:30

Dementia

94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
94
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Depressants01:28

Depressants

98
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agreement between relatives of Parkinson's patients and clinical observer in home diary assessments.

Journal of Parkinson's disease·2026
Same author

Personality Trait Changes After Device-Aided Therapy: Insights From Parkinson's Patients and Their Close Relatives.

Parkinson's disease·2025
Same author

Ethnographic evaluation of usability, understandability, and acceptance of the MY PD-CARE digital tool to facilitate Parkinson's disease symptom tracking and patients' and care partners' communications with the treating healthcare professional: the SELF-AWARE study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Authors' reply to Chaker Ben Salem's comment on: "Drug-Induced Cognitive Impairment".

Drug safety·2025
Same author

Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review.

Journal of Parkinson's disease·2025
Same author

The association between non-motor symptoms and cost in Parkinson's disease.

Journal of neurology·2025

Related Experiment Video

Updated: Jun 4, 2025

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

18.7K

Drug-Induced Cognitive Impairment.

Arne Reimers1,2, Per Odin3,4, Hanna Ljung3,4

  • 1Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Box 117, 22100, Lund, Sweden. arne.reimers@med.lu.se.

Drug Safety
|December 24, 2024
PubMed
Summary

Drug-induced cognitive impairment (DICI) affects individuals of all ages, encompassing various symptoms beyond dementia. Recognizing DICI is crucial to prevent long-term consequences from diverse medication classes.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.6K

Related Experiment Videos

Last Updated: Jun 4, 2025

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

18.7K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.6K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Medicine

Background:

  • Drug-induced cognitive impairment (DICI) is a significant clinical issue.
  • Existing research often focuses narrowly on elderly patients and specific drug classes.
  • DICI encompasses a spectrum of cognitive deficits, including subclinical symptoms, mild cognitive impairment (MCI), and delirium, affecting all age groups.

Purpose of the Study:

  • To broaden awareness of DICI beyond drug-induced dementia in the elderly.
  • To provide a comprehensive overview of DICI across various drug classes and age demographics.
  • To highlight the diverse types, symptoms, and potential mechanisms of DICI.

Main Methods:

  • Literature review of scientific papers on DICI.
  • Analysis of reported DICI types, symptoms, and suspected mechanisms.
  • Inclusion of studies across a wide range of drug classes and patient populations.

Main Results:

  • DICI is associated with numerous drug classes, including antiseizure medications, antidepressants, antipsychotics, opioids, and more.
  • Cognitive impairment can manifest as subclinical symptoms, MCI, or delirium.
  • DICI affects not only the elderly but also younger adults and children.

Conclusions:

  • DICI is a widespread complication of pharmacotherapy, affecting diverse populations.
  • Early recognition of even mild DICI is essential to mitigate potentially lifelong negative outcomes.
  • Further research and clinical attention are needed to address the full spectrum of DICI.